(RTTNews) - Biotechnology company Q32 Bio, Inc. (QTTB) announced Monday it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (AKBA). ADX-097, the lead product candidate ...
When the bactericidal properties of certain heat-labile blood components were initially described more than a century ago 1, no one could have imagined the considerable impact the complement system ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback